Cidara Therapeutics Inc.
Cidara Therapeutics Reports Second Quarter 2025 Financial Results and Corporate Updates
Summary
Cidara Therapeutics, Inc. reported its financial results for the second quarter ended June 30, 2025, highlighting positive top-line results from its Phase 2b NAVIGATE clinical trial for CD388, a non-vaccine solution for the prevention of seasonal influenza. The company also announced the closure of an upsized public offering for gross proceeds of $402.5 million, strengthening its balance sheet. Cidara's cash, cash equivalents, and restricted cash totaled $516.9 million as of June 30, 2025. The net loss for the second quarter was $25.7 million.
Profitelligence Alerts
Get alerts for CDTX
Be first to know when Cidara Therapeutics Inc. files with the SEC.
Filing Categories
Exhibits (1)
Advertisement
About Cidara Therapeutics Inc.
Cidara Therapeutics Inc. is a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel anti-infectives and immunotherapies. Its primary function involves addressing unmet medical needs in the treatment of serious infectious diseases and immune-based conditions. Emphasizing innovation, Cidara Therapeutics is known for its pioneering Cloudbreak platform, which integrates potent drug conjugates designed to address life-threatening bacterial, viral, and fungal infections. The asset prominently impacts the biotechnology and pharmaceutical sectors, endeavoring to transform standard infection treatments with its advanced therapeutic solutions. Cidara's pipeline includes the development of new antifungal agents like rezafungin, aimed at treating invasive fungal infections that significantly affect immunocompromised patients. With its strategic focus, Cidara Therapeutics plays a critical role in the emerging markets of antimicrobial resistance and immunotherapy. Positioned within the healthcare industry, Cidara's contributions hold significant potential to alter existing therapies and specialize in meeting complex medical challenges, reinforcing the broader landscape of pharmaceutical advancements and patient care strategies.
Official SEC Documents
Advertisement